ANTX Earnings & Financial Statements
AN2 Therapeutics, Inc.
$4.51
-$0.34(-7.01%)
53
Overall
60
Value
63
Tech
36
Quality
Market Cap
$183.02M
Volume
97.19K
52W Range
$1.00 - $7.19
Target Price
$9.00
ANTX earnings and financial statements: AN2 Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
ANTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating income | -$38.11M | -$56.79M | -$69.64M | -$42.26M |
| EBITDA | -$35.17M | -$51.32M | -$69.65M | -$44.70M |
| Net income | -$35.17M | -$51.32M | -$64.73M | -$40.96M |
| EPS (diluted) | $-1.16 | $-1.72 | $-2.74 | $-2.79 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | $61.95M | $92.09M | $138.74M | $102.56M |
| Total liabilities | $8.89M | $10.24M | $14.04M | $7.19M |
| Shareholders’ equity | $53.06M | $81.85M | $124.70M | $95.37M |
| Cash and equivalents | $19.94M | $21.35M | $15.65M | $27.22M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -$29.83M | -$49.26M | -$53.29M | -$33.46M |
| Free cash flow | -$29.83M | -$49.26M | -$53.29M | -$33.46M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ANTX | $4.51 | -7.0% | 97.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |